Finding out that the bacteria that live in your gut, on your skin, and in the back of your nose may be more knowledgeable about your health than your doctor is strangely humble. After reading the results from Stanford Medicine and a parallel international study that came to light in late 2025, that feeling is difficult to get rid of. When considered collectively, the research advances our knowledge of type 2 diabetes. It changes its shape.
86 participants were tracked for up to six years in the Stanford study, which was headed by Michael Snyder and published in Cell Host & Microbe. Samples from the skin, mouth, nose, and gut were taken by researchers every three months, and more frequently when participants became ill or took antibiotics. Over 118 million measurements from more than 5,400 biological samples were produced by the end. The extent of it is truly astounding. However, what they discovered made every sample worthwhile. The microbiome of people with type 2 diabetes was less stable, less diverse, and more prone to abrupt fluctuations; this was an internal disorder that persisted even after the disease “settled in.” “With diabetes, that signature is the same in many ways except that it is long-term rather than temporary,” stated lead author Xin Zhou.
| Field | Details |
|---|---|
| Institution | Stanford Medicine |
| Lead Researcher | Michael Snyder, PhD — Stanford W. Ascherman Professor in Genetics |
| Study Published In | Cell Host & Microbe (March 12, 2024) |
| Participants Tracked | 86 people, ages 29–75, over up to 6 years |
| Total Measurements | 118,124,374 data points from 5,432 biological samples |
| Key Molecule Discovered | Trimethylamine (TMA) — produced by gut microbes from dietary choline |
| Related Parallel Research | Nature Metabolism, Université catholique de Louvain / Imperial College London |
| Immune Target | IRAK4 — a protein that drives chronic inflammation tied to insulin resistance |
| Funding Body | NIH Integrative Human Microbiome Project |
| Global Impact | Type 2 diabetes affects over 500 million people worldwide |
It’s difficult to ignore how much this alters our perception of the internal appearance of a diseased body. The microbiome is not merely an observer. It’s responding, changing, attempting to make up for it, and apparently, for those who have diabetes, losing that fight gradually and covertly over many years.
When compared to a different study from Imperial College London and the Université catholique de Louvain, which was published in Nature Metabolism in December 2025, the Stanford results took on a different significance. Under the direction of Professors Marc-Emmanuel Dumas and Patrice Cani, that team discovered a particular molecule called trimethylamine, or TMA, which is created when gut microbes break down dietary choline. TMA’s actions are nearly paradoxical. It attaches itself to IRAK4, a protein that typically triggers inflammation in reaction to a high-fat diet, and reduces it. It seems to restore the body’s capacity to react to insulin in this way. Additionally, the same molecule prevented mice from dying from sepsis. It is worth pausing to consider that detail, which is easily missed in the press releases.
Nearly 20 years ago, Cani’s early research on gut bacteria and diet-induced inflammation was met with a great deal of skepticism, which set the stage for this discovery. It was, at best, a fringe theory in 2005 that bacterial components from the gut could enter the bloodstream and cause insulin resistance. It is no longer the case. Since then, the scientific community has caught up, so the new TMA findings feel more like an overdue confirmation than a surprise. Science can occasionally proceed in this manner: gradual accumulation followed by abrupt clarity.
The fact that the IRAK4 pathway is not a novel target makes it especially intriguing. IRAK4 inhibitor medications have been developed by pharmaceutical companies to treat various ailments. This suggests that something the body can naturally produce from food could mimic or enhance the effects of those drugs. Although the mouse studies are encouraging, it is never easy to translate that into clinical reality, so it is still unclear whether TMA could eventually be administered as a supplement or dietary intervention in humans. Given the history of diabetes medication development, it seems reasonable that researchers are being cautiously optimistic.
One more noteworthy observation was made by Snyder’s team back at Stanford. The bacteria that are most specific to a person—those that create a sort of microbial fingerprint—were also the most likely to endure over time. This terrain is being shaped by your immune system, diet, and genetics. This implies that there won’t likely be a one-size-fits-all approach to microbiome-based diabetes treatments. Here, personalized medicine is more than just a catchphrase—it might even be a biological requirement. It probably depends on who is asking whether that lengthens or improves the course of treatment. It’s possible that the solution has been there all along for the 500 million people with type 2 diabetes worldwide.
